Sandra L. Preston

Pharmacodynamics of Levofloxacin

Sandra L. Preston · JAMA · 1998 · 587 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint

George L. Drusano, Sandra L. Preston, C. Hardalo et al. · Antimicrobial Agents and Chemotherapy · 2001 · 242 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Relationship between Fluoroquinolone Area under the Curve:Minimum Inhibitory Concentration Ratio and the Probability of Eradication of the Infecting Pathogen, in Patients with Nosocomial Pneumonia

George L. Drusano, Sandra L. Preston, Cynthia L. Fowler et al. · The Journal of Infectious Diseases · 2004 · 241 citations

Pharmacy, Infectious Diseases, Pharmacology +17

A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)

Daniel S. Stein, Douglas G. Fish, John A. Bilello et al. · AIDS · 1996 · 176 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Cellular Mechanism of the Antigonadotropic Action of Luteinizing Hormone-Releasing Hormone in the Corpus Luteum*

Harold R. Behrman, Sandra L. Preston, Alan Hall · Endocrinology · 1980 · 132 citations

Life Sciences, Endocrinology, Pharmacology +17